Table 1. Outcome data from the LIBRETTO-001 study of selpercatinib in patients with RET fusion-positive non-small cell lung cancer [NB1]5.
| Previously treated patients (n=247) | Treatment-naive patients (n=69) | |
|---|---|---|
| Objective response rate | 61.5% | 82.6% |
| Complete response rate | 8.1% | 7.2% |
| Time to response (median) | 1.9 months (range 0.7 to 44.2) | 1.8 months (range 0.7 to 10.8) |
| Progression-free survival (median) | 26.2 months | 22.0 months |
| Overall survival (median) | 47.6 months | Not reached [NB2] |
NB1: Outcomes were assessed by a blinded independent review committee following Response Evaluation Criteria in Solid Tumours (RECIST v1.1) guidelines.
NB2: Median overall survival was not able to be calculated for treatment-naive patients, as 52.3% were still alive at final follow-up.5